Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Climate engineering would alter the oceans, reshaping marine life – our new study examines each method’s risks - 2'Here we go again': Businesses grapple with fuel costs
- 3The 10 Most Noteworthy Games in History
- 4Best Amusement Park in Asia: Which One Is a Must-Visit
- 5Orcas seen hunting great white sharks to eat their livers in drone footage recorded in Mexico
- Why the chemtrail conspiracy theory lingers and grows – and why Tucker Carlson is talking about it
- The Most Notable Design Brands of the 21st Hundred years
- German men need approval for stays abroad under military service law
- The most effective method to Go with Informed Choices on Vehicle Leases
- ‘Wicked: For Good’ streaming release — How to watch the sequel starring Ariana Grande and Cynthia Erivo
- Equality requires universal draft, participation in economy and workforce, MK Liberman says
- A quick recap of 'Stranger Things' Seasons 1-4, plus key episodes to rewatch before Volume 1 of the final season drops
- Space Condos to Lift Your Metropolitan Living
- First SpaceX booster for upgraded Starship fails during test in Texas
